eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases
MELAS Syndrome: Follow-up
Updated: Jul 23, 2009
Follow-up
Further Inpatient Care
- Admit for medical management of strokelike episodes and seizures.
- Admit for metabolic decompensation or signs of diabetic ketoacidosis. Diabetes appears to be the most common manifestation of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS) syndrome.
- Admit for signs of cardiac arrhythmia (Wolff-Parkinson-White syndrome), hypertension, impending aortic root dissection, or congestive heart failure (CHF) associated with hypertrophic or dilated cardiomyopathy.
- Admit for signs of nephrotic syndrome that may present in association with focal segmental glomerulosclerosis.
- Admit if a sign of acute abdomen is present; acute abdomen may be an indication of pancreatitis.
Further Outpatient Care
- Carefully monitor the progress of the encephalomyopathy and sequelae.
- Neurodevelopmental testing is appropriate because progressive intellectual deterioration follows stroke-like episodes of MELAS syndrome. Neuropsychological evaluation is appropriate for presence of autism spectrum disorder (ASD).
- Monitor growth curves because mitochondrial disorders such as MELAS syndrome are associated with short stature or failure to thrive.
- Refer the patient to an ophthalmologist to monitor for pigmentary degeneration of the retina, which may be similar to that observed in patients with neuropathy, ataxia, and retinitis pigmentosa syndrome. Closely monitor signs (eg, ophthalmoplegia, ptosis).
- Carefully monitor individuals with MELAS syndrome for hearing loss with a hearing evaluation, including distortion product otoacoustic emissions and auditory brainstem evoked responses.
- Carefully monitor patients for cardiomyopathy and measure Z-score for aortic root diameter with echocardiography. Request an ECG as a baseline study to monitor for conduction defects, even if patients are asymptomatic.
- Carefully monitor patients for type 2 diabetes, hypothyroidism, hyperthyroidism, and parathyroid dysfunction.
- Carefully monitor patients for the persistence of lactic acidosis.
- 1 H-MRS of the brain may be used to monitor potential therapeutic efficacy if increased permeability of the blood-brain barrier is a concern.
Inpatient & Outpatient Medications
- Medications include the following:
- Compounds that may increase ATP production or transfer of electrons (eg, ascorbate, riboflavin, CoQ10, vitamins K-1 and K-3, nicotinamide, creatine monohydrate)
- Compounds that can be used to prevent a possible secondary carnitine deficiency or secondary dysfunction of fatty acid oxidation (eg, carnitine)
- Compounds that can be used to prevent or ameliorate the progression of stroke-like episodes (eg, L-arginine): L-arginine could modulate mitochondrial energy metabolism by inhibiting glutamate uptake into mitochondria and decreasing neurotoxicity associated with nitric oxide-mediated mitochondrial dysfunction.
- Compounds that may be used to treat lactic acidosis (eg, dichloroacetate)
- Dichloroacetate stimulates pyruvate dehydrogenase function by inhibiting pyruvate dehydrogenase kinase, the enzyme that normally phosphorylates and inactivates pyruvate dehydrogenase. Therefore, in conditions that result in the accumulation of lactate and alanine, activation of pyruvate dehydrogenase decreases the release of these compounds from peripheral tissues and enhances their oxidative metabolism by the liver.
- This medication has been used to treat lactic acidosis in adult and pediatric patients. Anecdotal reports detail successful treatment in patients with MELAS syndrome. Dichloroacetate has been administered orally at doses of 12.5-100 mg/kg/d. This medication is available only under research protocols in the United States.
- If seizures have developed as part of the condition, do not use valproic acid as an anticonvulsant, since incidents of pancreatitis following valproate administration have occurred and valproic acid has been associated with mitochondrial toxicity.
- Use phenobarbital with caution, because the drug has demonstrated inhibition of the respiratory chain in vitro.
Transfer
- Transfer to a tertiary care center may be required to better coordinate the diagnostic evaluation to include the following:
- Muscle biopsy
- Evaluation for mitochondrial enzyme defects
- Analysis of mtDNA mutation
- If diagnosis is already known and the patient has been stabilized, transfer may be required for better management of complications such as the following:
- Pancreatitis
- Cardiac arrhythmias
- Cardiomyopathy
- Ketoacidosis
- Stroke-like episodes
Deterrence/Prevention
- If conditions such as cardiomyopathy are present, restrict exercise.
- Although the long-term effects of dietary manipulations are unknown, ensure good nutritional status, good hydration, and avoidance of fasting as part of a supportive plan.
- A mild degree of aerobic activity may lead to an improvement of aerobic capacity. Restrict strenuous exercise because of the possible complication of rhabdomyolysis.
- Information on the therapeutic efficacy of reported compounds used as nutritional supplements are limited; however, most do not have any serious adverse effects. Nutritional supplements may help to prevent further deterioration in some individuals; however, further research is warranted.
Complications
- Failure to thrive and short stature
- Progressive intellectual deterioration and decline that eventually may lead to dementia
- Psychosis with depression, schizophrenia, or bipolar disorder
- Autism spectrum disorders (ASDs)
- Sensorineural hearing loss
- Endocrine dysfunction with hypogonadism, diabetes, hypoparathyroidism, hypothyroidism, and hyperthyroidism
- CHF from cardiomyopathy and sudden death from conduction defects
- Visual difficulties related to pigmentary degeneration of the retina or cortical blindness as one of the sequelae of progressive cortical atrophy and strokelike episodes
- End-stage renal failure as a complication of focal segmental glomerulosclerosis
- Acute renal failure secondary to rhabdomyolysis
- GI dysfunction secondary to intestinal pseudoobstruction or pancreatitis
- Aortic root dissection (reported in one kindred; requires further studies to evaluate the prevalence)
Prognosis
- MELAS syndrome widely varies in presentation; however, patients in general tend to have a poor prognosis and outcome.
- The encephalomyopathy tends to be severe and progressive to dementia. The patient with MELAS syndrome may end up in a state of cachexia.
- Currently, no therapies have proven efficacy.
Patient Education
- Once the diagnosis is established, refer the patient and family for genetic counseling and evaluation of other family members who may be at risk of being affected.
- Educate the family concerning further deteriorations and complications (eg, cardiomyopathy, nephrotic syndrome, deafness, diabetes, GI difficulties) that may affect the proband. In general, educate the family about maintaining a good nutritional and hydration status, and discuss information concerning current trials (eg, use of dichloroacetate for persistent lactic acidosis in individuals with MELAS syndrome).
- For excellent patient education resources, visit eMedicine's Stroke Center. Also, see eMedicine's patient education article Stroke.
Miscellaneous
Medicolegal Pitfalls
- Failure to evaluate for or exclude mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS) syndrome in individuals with strokelike episodes or clinical presentations of encephalomyopathy when other causes have been excluded, unnecessarily delaying diagnosis and counseling
- Failure to recognize that diabetes mellitus, either associated or not associated with deafness, may be a presentation of MELAS syndrome
- Failure to recognize that GI symptoms may be a presentation of MELAS syndrome
- Failure to recognize other less common presentations (eg, nephrotic syndrome, dilated cardiomyopathy, pigmentary retinopathy)
- Failure to investigate other members of the family for possible risk of MELAS syndrome
- Failure to pursue a muscle biopsy to identify the MELAS mutation if the evaluation of blood studies is unremarkable and the condition is still suspected
Special Concerns
- Anticipate less frequent complications, such as the following:
- Cardiomyopathy
- Conduction defects
- Aortic root dissection
- Pancreatitis
- Intestinal pseudoobstruction
- Peripheral neuropathy
- Nephrotic syndrome
- Ischemic colitis
- Rhabdomyolysis
- Psychiatric (affective disorders) or behavioral abnormalities (autism spectrum disorders [ASDs])
- Endocrine dysfunction (eg, hyperthyroidism, hypothyroidism)
More on MELAS Syndrome |
| Overview: MELAS Syndrome |
| Differential Diagnoses & Workup: MELAS Syndrome |
| Treatment & Medication: MELAS Syndrome |
 Follow-up: MELAS Syndrome |
| Multimedia: MELAS Syndrome |
| References |
| « Previous Page | Next Page » |
References
Mehrazin M, Shanske S, Kaufmann P, Wei Y, Coku J, Engelstad K. Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS. Am J Med Genet A. Feb 15 2009;149A(4):584-7. [Medline].
Sasarman F, Antonicka H, Shoubridge EA. The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. Hum Mol Genet. Dec 1 2008;17(23):3697-707. [Medline].
Nemes A, Geleijnse ML, Sluiter W, Vydt TC, Soliman OI, van Dalen BM. Aortic distensibility alterations in adults with m.3243A>G MELAS gene mutation. Swiss Med Wkly. Feb 21 2009;139(7-8):117-20. [Medline].
[Guideline] International Diabetes Center. Type 2 diabetes practice guidelines. 2003;[Full Text].
Betts J, Jarost E, Perry RH et al. Molecular neuropathology of MELAS; level of heteroplasmy in individual neurons and evidence of extensive vascular involvement. Neuropathology and Applied. Neurobiology. 2006;32:359-373.
Borner GV, Zeviani M, Tiranti V, et al. Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum Mol Genet. Mar 1 2000;9(4):467-75. [Medline].
Ciafaloni E, Ricci E, Shanske S, et al. MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol. Apr 1992;31(4):391-8. [Medline].
Deschauer M, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM. MELAS associated with mutations in the POLG1 gene. Neurology. May 15 2007;68(20):1741-2. [Medline].
Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol. Jan 1994;9(1):4-13. [Medline].
Hirano M, Ricci E, Koenigsberger MR, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 1992;2(2):125-35. [Medline].
Jacobs HT, Holt IJ. The np 3243 MELAS mutation: damned if you aminoacylate, damned if you don't. Hum Mol Genet. Mar 1 2000;9(4):463-5. [Medline].
Joko T, Iwashige K, Hashimoto T, et al. A case of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes associated with diabetes mellitus and hypothalamo-pituitary dysfunction. Endocr J. Dec 1997;44(6):805-9. [Medline].
Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. Feb 14 2006;66(3):324-30. [Medline].
Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. Feb 22 2005;64(4):710-2. [Medline].
Matsumoto J, Saver JL, Brennan KC, Ringman JM. Mitochondrial encephalomyopathy with lactic acidosis and stroke (MELAS). Rev Neurol Dis. Winter 2005;2(1):30-4. [Medline].
Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. Oct 1984;16(4):481-8. [Medline].
Pons R, Andreu AL, Checcarelli N, Vila MR, Engelstad K, Sue CM. Mitochondrial DNA abnormalities and autistic spectrum disorders. J Pediatr. Jan 2004;144(1):81-5. [Medline].
Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs. 2006;20(6):443-64. [Medline].
Shanske S, Coku J, Lu J, Ganesh J, Krishna S, Tanji K. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: evidence from 12 cases. Arch Neurol. Mar 2008;65(3):368-72. [Medline].
Shimotake T, Furukawa T, Inoue K, Iwai N, Takeuchi Y. Familial occurrence of intestinal obstruction in children with the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). J Pediatr Surg. Dec 1998;33(12):1837-9. [Medline].
Sue CM, Bruno C, Andreu AL, et al. Infantile encephalopathy associated with the MELAS A3243G mutation. J Pediatr. Jun 1999;134(6):696-700. [Medline].
Tanahashi C, Nakayama A, Yoshida M, Ito M, Mori N, Hashizume Y. MELAS with the mitochondrial DNA 3243 point mutation: a neuropathological study. Acta Neuropathol. Jan 2000;99(1):31-8. [Medline].
Tay SH, Nordli DR Jr, Bonilla E, Null E, Monaco S, Hirano M. Aortic rupture in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Arch Neurol. Feb 2006;63(2):281-3. [Medline].
Thambisetty M, Newman NJ, Glass JD, Frankel MR. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist. Sep 2002;8(5):302-12. [Medline].
Further Reading
Keywords
MELAS syndrome, mitochondrial encephalomyopathy, lactic acidosis, stroke, oxidative phosphorylation, OXPHOS disorder, strokelike episode, seizures, diabetes mellitus, hearing loss, cardiac disease, short stature, endocrinopathies, exercise intolerance, neuropsychiatric dysfunction, hemiplegia, hemianopia, schizophrenia, bipolar disorder, autism spectrum disorders, ASD, hypertrophic cardiomyopathy, hypertension, atrioventricular blocks, long QT syndrome, Wolff-Parkinson-White syndrome, Leigh syndrome, subacute necrotizing encephalopathy, hypothyroidism, hyperthyroidism, developmental delay, learning disability, attention deficit disorder, polydipsia, polyuria, nephrotic syndrome, treatment, diagnosis
